Thursday, October 29, 2020 4:55:23 PM
Everyone following Anavex, pro or con, has been pondering what might result from Anavex's 15 minutes of mic-time at the CTAD conference. Very well; appropriate.
But, how will the Aussies respond; if at all? How might they handle very positive reports in the media of "New American drug successfully treats Parkinson's disease dementia?"
If results are positive (they will be), both the American Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) will be questioned by both media reporters and the general public about blarcamesine. Of course, at least with the FDA, the standard "...data are incomplete; further studies are required" dictum will be the first, and probably only thing stated.
But with solid data, with people actually being known to be safely, successfully treated for their dementia, public conversation about the drug and its results will be prominent. The words "Anavex" and "blarcamesine" will be more widely known and encountered; just as happened with "penicillin."
The Anavex snowball is now at the top of the hill.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM